Results 11 to 20 of about 120,194 (305)

Vigil

open access: yesApparatus. Film, Media and Digital Cultures of Central and Eastern Europe, 2020
Tibor Hajas's video and article.
Tibor Hajas
doaj   +4 more sources

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer

open access: yesClinical Medicine Insights: Oncology, 2022
Background: Gemogenovatucel-T (Vigil) is a triple-function autologous tumor cell immunotherapy which expresses granulocyte-macrophage colony-stimulating factor and decreases expression of furin and downstream TGF-β1 and TGF-β2.
Minal Barve   +7 more
doaj   +2 more sources

Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6

open access: yesVaccines, 2021
Colorectal cancer is the third most diagnosed cancer in the United States. Five-year survival rates remain low and many patients will develop liver metastasis.
Vedin Barve   +8 more
doaj   +2 more sources

Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials

open access: yesFrontiers in Oncology, 2022
In recent years, many clinical trials have shown the safety and efficacy of Gemogenovatucel-T (Vigil) in the treatment of advanced OC patients. The purpose of this study was to explore the safety and efficacy of Gemogenovatucel-T (Vigil) in the first ...
Yixin Zhang   +7 more
doaj   +2 more sources

The Vigil Magnetometer for Operational Space Weather Services From the Sun‐Earth L5 Point

open access: yesSpace Weather
Severe space weather has the potential to cause significant socio‐economic impact and it is widely accepted that mitigating this risk requires more comprehensive observations of the Sun and heliosphere, enabling more accurate forecasting of significant ...
J. P. Eastwood   +12 more
doaj   +2 more sources

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy. [PDF]

open access: hybridFuture Oncol
We describe in this review the historical evidence leading up to the concept and design of Vigil and subsequent clinical applications including safety and efficacy in a randomized, controlled Phase IIB trial.
Nemunaitis J   +13 more
europepmc   +4 more sources

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer

open access: yesVaccines, 2021
Aim: To determine the relationship between gene expression profile (GEP) and overall survival (OS) by NanoString following treatment with Vigil. Patients and Methods: Recurrent ovarian cancer patients (n = 21) enrolled in prior clinical trials.
Rodney P. Rocconi   +10 more
doaj   +2 more sources

Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product. [PDF]

open access: goldSci Rep
Retrospective data support overall survival (OS) advantage to high clonal tumor mutation burden (cTMB), high clonal neoantigen load (cNEO) and low intratumor heterogeneity (ITH) in cancer patients who receive immunotherapy.
Willoughby D   +10 more
europepmc   +3 more sources

Measurement of Airway Responsiveness on Vigil and Unrestrained Mouse [PDF]

open access: bronzeBio-Protocol, 2013
Airway hyperresponsiveness to methacholine is an important characteristic of asthma. This protocol describes how to measure airway response to methacholine in vigil and unrestraint mouse.
François Daubeuf   +2 more
doaj   +2 more sources

Recuperación colectiva de la Biblioteca Popular Constancio C. Vigil

open access: diamondA&P Continuidad, 2019
El presente artículo tiene como objetivo narrar la experiencia del Proyecto de extensión “Recuperación Colectiva de la Biblioteca Vigil”. El mismo resultó del trabajo en conjunto entre la currícula de grado del Taller de Proyecto Arquitectónico, el ...
Susana Paganini
doaj   +2 more sources

Home - About - Disclaimer - Privacy